Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB
A Phase 1 Study of [ 14 C]-Ixazomib to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphoma
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Ohio
-
Cleveland、Ohio、アメリカ
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Each participant must meet all of the following inclusion criteria to be enrolled in the study:
- 18 years or older
- Histologic or cytologic diagnosis of advanced or metastatic solid tumor or lymphoma for which no standard, curative, or life-prolonging therapies exist or are effective
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
- Female participants who are postmenopausal for at least 1 year OR are surgically sterile OR if of childbearing potential, agree to practice 2 effective methods of contraception at the same time during the entire study through 90 days after the last dose of study drug OR agree to practice true abstinence
- Male participants who agree to practice effective barrier contraception during the entire study and through 90 days after the last dose of study drug OR agree to practice true abstinence
- Voluntary written consent
- Suitable venous access for the conduct of blood sampling
- Recovered from the reversible effects of prior anticancer therapy
Exclusion Criteria:
Participants meeting any of the following exclusion criteria are not to be enrolled in the study:
- Female participants who are lactating or breastfeeding or have a positive serum pregnancy test
- Serious medical or psychiatric illness that could interfere with the study
- Treatment with any investigational products or radiotherapy within 21 days before the first dose of study drug
- Peripheral neuropathy greater than (>) Grade 2
- Systemic treatment with strong and moderate inhibitors of CYP1A2, strong and moderate inhibitors of CYP3A, or clinically significant CYP3A inducers or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study drug
- Symptomatic brain metastasis. Participants with brain metastases: must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy; and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs)
- Ongoing treatment with corticosteroids
- Major surgery within the 14 days preceding the first dose of study drug
- Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before the first dose of study drug
- Life-threatening illness unrelated to cancer
- Known hepatitis B surface antigen -positive, or known or suspected active hepatitis C infection or human immunodeficiency virus (HIV) positive
- Diagnosed or treated for another malignancy within 2 years before the first dose, OR previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
- Any cardiovascular condition specified in the study protocol
- Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of IXAZOMIB
- History of urinary and/or fecal incontinence
- Inability to comply with study procedures or visit schedule including the requirement for inpatient confinement
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:IXAZOMIB
Part A: Participants will receive a single dose of 4.1-milligram (mg) [14C]-IXAZOMIB oral solution containing approximately 500-nCurie (nCi) of total radioactivity on Day 1 and remain at the clinic for 8 days. On Days 14 and 21, participants may be administered a single 4.0-mg capsule of IXAZOMIB. Participants will return to the clinic in the evening before Days 14, 21, 28, and 35 for a 24-hour overnight clinic visit. Part B: Eligible participants from Part A may continue into Part B once they have completed their Day 35 assessments in Part A. Participants may receive IXAZOMIB capsules administered orally at a dose of 4.0-mg once weekly on Days 1, 8, and 15 of 28-day cycles. Participants will continue in this study until disease progression or unacceptable toxicity. |
Part A: Ixazomib 4.1 mg containing approximately 500-nCi [14C]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21. Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib
時間枠:Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Maximum observed plasma concentration (Cmax) is the peak plasma concentration of ixazomib, obtained directly from the plasma concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Part A: Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for Ixazomib
時間枠:Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Time to reach the maximum observed plasma concentration (Cmax), equal to time (hours) to Cmax of ixazomib after administration, obtained directly from the plasma concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Part A: AUC(0-312): Area Under the Plasma Concentration-time Curve From Time 0 to 312 Hrs Post-dose for Ixazomib
時間枠:Day 1 of Part A pre-dose and at multiple timepoints (up to 312 hrs) post-dose
|
AUC(0-312) is a measure of the area under the plasma concentration time-curve from time zero to 312 hrs post-dose for ixazomib.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to 312 hrs) post-dose
|
Part A: Cmax: Maximum Observed Plasma Concentration of TRA
時間枠:Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Maximum observed plasma concentration (Cmax) of TRA is the peak plasma concentration of TRA, obtained directly from the plasma TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Tmax: Time to Reach the Cmax for TRA
時間枠:Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Time to reach the maximum observed plasma concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the plasma TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: AUC(0-816): Area Under the Plasma Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA
時間枠:Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
AUC(0-816) is a measure of the area under the plasma concentration time-curve from time zero to 816 hrs post-dose for TRA.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
Part A: Cmax: Maximum Observed Whole Blood Concentration of TRA
時間枠:Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Maximum observed whole blood concentration (Cmax) of a TRA is the peak whole blood concentration of TRA, obtained directly from the whole blood TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Tmax: Time to Reach the Maximum Observed Whole Blood Concentration (Cmax) for TRA
時間枠:Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Time to reach the maximum observed whole blood concentration (Cmax) for TRA, equal to time (hours) to Cmax for TRA after administration, obtained directly from the whole blood TRA concentration-time curve.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: AUC(0-816): Area Under the Whole Blood Concentration-time Curve From Time 0 to 816 Hrs Post-dose for TRA
時間枠:Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
AUC(0-816) is a measure of the area under the whole blood concentration time-curve from time zero to 816 hrs post-dose for TRA.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to 816 hrs) post-dose
|
Part A: Cumulative Percentage of Ixazomib Dose Recovered in the Urine
時間枠:Day 1 of Part A from 0 to pre-dose and at multiple timepoints (up to 168 hrs) post-dose
|
Percentage of the ixazomib dose excreted unchanged in the urine from 0 to 168 hrs post-dose.
|
Day 1 of Part A from 0 to pre-dose and at multiple timepoints (up to 168 hrs) post-dose
|
Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Feces
時間枠:Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Percentage of the TRA dose excreted in feces from Day 1 to Day 35 of Part A
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Cumulative Percentage of the Total Radioactivity Dose Excreted in Urine
時間枠:Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Percentage of the TRA dose excreted in urine from Day 1 to Day 35 of Part A.
|
Day 1 of Part A pre-dose and at multiple timepoints (up to Day 35) post-dose
|
Part A: Renal Clearance of Ixazomib
時間枠:Day 1 pre-dose and at multiple timepoints (up to Day 14) post-dose
|
Renal clearance is the volume of plasma from which ixazomib is completely removed by the kidney in a given amount of time, calculated as the amount of ixazomib excreted in the urine divided by the area under the plasma ixazomib concentration-time curve.
|
Day 1 pre-dose and at multiple timepoints (up to Day 14) post-dose
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Ixazomib and Metabolites as Percent of Total Radioactivity in Plasma
時間枠:Day 1 pre-dose and at multiple time points (up to 816 hrs) post-dose
|
The plasma samples were pooled for participants over 816 hrs post-dose, and data was analysed using the Hamilton method time-proportional pooling, and therefore the data is reported as "percent of total radioactivity in plasma" with measure type as "number" and measure dispersion as "Not applicable, NA".
|
Day 1 pre-dose and at multiple time points (up to 816 hrs) post-dose
|
Ixazomib and Metabolites as Percent of Total Dose Administered in Urine
時間枠:Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled urine.
The data is therefore reported as "percentage of dose" with measure type as "number" and measure dispersion as "NA".
|
Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
Ixazomib and Metabolites as Percent of Total Dose Administered in Feces
時間枠:Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
The 35-day post-dose data is extrapolated from the average of four participant data from 0-168-hr pooled feces.
The data is therefore reported as "percentage of dose" with measure type as "number" and measure dispersion as "NA".
|
Day 1 pre-dose and at multiple time points (up to Day 35) post-dose
|
Number of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
時間枠:Baseline up to Cycle 5 Day 45
|
Baseline up to Cycle 5 Day 45
|
|
Number of Participants With TEAEs Related to Investigations System Organ Class for Laboratory Values
時間枠:Baseline up to Cycle 5 Day 45
|
Baseline up to Cycle 5 Day 45
|
|
Number of Participants With TEAEs Related to Vital Signs
時間枠:Baseline up to Cycle 5 Day 25
|
Vital signs included oral body temperature, heart rate, and blood pressure.
|
Baseline up to Cycle 5 Day 25
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
IXAZOMIBの臨床試験
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.募集
-
University of LeedsTakeda; Cancer Research UK募集